All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
How do you incorporate MRD into treatment decision-making in clinical practice?
Featured:
Koen Van BesienDuring Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?
How do you incorporate MRD into treatment decision-making in clinical practice?
Van Besien begins by discussing the complexities around the two major technologies we use to detect MRD, flow cytometry and molecular testing. He outlines reliable MRD tests, settings in which they can be used, and treatment options, such as MRD testing during induction for MPN1 mutated AML. He also describes the necessity for allogenic transplant consolidation in MRD- patients. Finally, he highlights the increasing data on maintenance therapy for patients that remain MRD+ e.g. TKI inhibitors.